Aboshouk Dalia R, Youssef M Adel, Bekheit Mohamed S, Hamed Ahmed R, Girgis Adel S
Department of Pesticide Chemistry, National Research Centre Dokki Giza 12622 Egypt
Department of Chemistry, Faculty of Science, Helwan University Helwan Egypt.
RSC Adv. 2024 Feb 14;14(9):5690-5728. doi: 10.1039/d3ra08962b.
Cancer is one of the most significant health challenges worldwide. Various techniques, tools and therapeutics/materials have been developed in the last few decades for the treatment of cancer, together with great interest, funding and efforts from the scientific society. However, all the reported studies and efforts seem insufficient to combat the various types of cancer, especially the advanced ones. The overexpression of tyrosine kinases is associated with cancer proliferation and/or metastasis. VEGF, an important category of tyrosine kinases, and its receptors (VEGFR) are hyper-activated in different cancers. Accordingly, they are known as important factors in the angiogenesis of different tumors and are considered in the development of effective therapeutic approaches for controlling many types of cancer. In this case, targeted therapeutic approaches are preferable to the traditional non-selective approaches to minimize the side effects and drawbacks associated with treatment. Several indole-containing compounds have been identified as effective agents against VEGFR. Herein, we present a summary of the recent indolyl analogs reported within the last decade (2012-2023) with potential antineoplastic and VEGFR inhibitory properties. The most important drugs, natural products, synthesized potent compounds and promising hits/leads are highlighted. Indoles functionalized and conjugated with various heterocycles beside spiroindoles are also considered.
癌症是全球最重大的健康挑战之一。在过去几十年里,人们开发了各种技术、工具和治疗方法/材料来治疗癌症,科学界也对此投入了极大的兴趣、资金和精力。然而,所有已报道的研究和努力似乎都不足以对抗各种类型的癌症,尤其是晚期癌症。酪氨酸激酶的过度表达与癌症增殖和/或转移有关。血管内皮生长因子(VEGF)是酪氨酸激酶的一个重要类别,其受体(VEGFR)在不同癌症中过度激活。因此,它们被认为是不同肿瘤血管生成的重要因素,并被纳入控制多种癌症的有效治疗方法的研发中。在这种情况下,靶向治疗方法比传统的非选择性方法更可取,以尽量减少与治疗相关的副作用和缺点。几种含吲哚的化合物已被确定为抗VEGFR的有效药物。在此,我们总结了近十年(2012 - 2023年)报道的具有潜在抗肿瘤和VEGFR抑制特性的吲哚类似物。重点介绍了最重要的药物、天然产物、合成的强效化合物以及有前景的活性化合物/先导化合物。还考虑了与各种杂环官能化和共轭的吲哚以及螺吲哚。